Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474851A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence
08/07/2003CA2474850A1 Imidazo[1,2-a]pyridine derivatives
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
08/07/2003CA2474835A1 Immediate release dosage forms containing solid drug dispersions
08/07/2003CA2474821A1 Anti-viral compounds
08/07/2003CA2474813A1 A novel dosage form of l-methionine s-sulfoximine
08/07/2003CA2474809A1 Dry granulated formulations of azithromycin
08/07/2003CA2474759A1 Gene for peripheral arterial occlusive disease
08/07/2003CA2474718A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterial, related compositions and methods
08/07/2003CA2474717A1 Cosmetic or dermatological use of vitamin a or the esters thereof in combination with a partly methylated beta-cyclodextrin
08/07/2003CA2474710A1 Freeze-dried pharmaceutically acceptable inclusion complexes of propofol and cyclodextrin
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474690A1 Composition for inhalation
08/07/2003CA2474593A1 N, n'-dimethylated n-confused porphyrins
08/07/2003CA2474590A1 Treatment of male sexual dysfunction
08/07/2003CA2474588A1 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
08/07/2003CA2474456A1 5-ring heterocycles used as antiviral agents
08/07/2003CA2474447A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003CA2474434A1 Condensed heterocyclic compounds
08/07/2003CA2474433A1 Arylsulfonamidobenzylic compounds
08/07/2003CA2474414A1 Oligonucleotides comprising alternating segments and uses thereof
08/07/2003CA2474349A1 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003CA2474339A1 Multiple virus replicon culture systems
08/07/2003CA2474316A1 Kappa-pviia-related conotoxins as organ protectants
08/07/2003CA2474306A1 Selective analgesic agents
08/07/2003CA2474277A1 2,4-pyrimidinediamine compounds and their uses
08/07/2003CA2474135A1 Bicyclic cb2 cannabinoid receptor ligands
08/07/2003CA2474012A1 Auger effect-based cancer therapy method
08/07/2003CA2474000A1 Alpha 2 delta ligands to treat tinnitus
08/07/2003CA2473990A1 Modulation of type ii.beta. phosphoinositide phosphate kinase
08/07/2003CA2473984A1 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473797A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003CA2473457A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003CA2473250A1 Fractionation of phytosterol esters in oil
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473231A1 Resistance-repellent retroviral protease inhibitors
08/07/2003CA2473169A1 Compounds that inhibit factor xa activity
08/07/2003CA2473164A1 Novel compounds that inhibit factor xa activity
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2473158A1 Treatment of rheumatoid arthritis using imatinib
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2472342A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003CA2472296A1 Fap-activated anti-tumor compounds
08/07/2003CA2472103A1 Transmucosal delivery of proton pump inhibitors
08/07/2003CA2471934A1 Crystalline hydrochloride of 7-(((5-amino-1,2,4-thiadiazol-3-yl)(fluoromethoxyimino)acetyl)amino)-3-((imino-1-piperazinylmethyl)methylhydrazono)-methyl-3-cephem-4-carboxylic acid
08/07/2003CA2471850A1 A method and system for treating an atrial arrhythmia
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2453770A1 Compositions for preventing human cancer and method of preventing human cancer
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333094A2 Human telomerase catalytic subunit
08/06/2003EP1333033A1 FAP-activated anti-tumor compounds
08/06/2003EP1333028A1 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
08/06/2003EP1333026A1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis
08/06/2003EP1333022A2 Compounds containing derivatives of cyclopentane and their use to stimulate skin peeling
08/06/2003EP1333021A2 Compositions containing derivatives of jasmonic acid and their use for stimulating skin peeling
08/06/2003EP1332764A1 A mucoadhesive thermoresponsive medicament-carrier composition
08/06/2003EP1332763A1 High-density lipoprotein-cholesterol level elevating agent
08/06/2003EP1332759A1 Pharmaceutical and nutritional compositions containing a di- or oligosaccharide as insulin secretion promoter
08/06/2003EP1332758A1 Dermatological compositions comprising a corticosteroid and zinc pyrithione
08/06/2003EP1332757A1 Efavirenz compressed tablet formulation
08/06/2003EP1332756A2 Compositions and methods for restoring a normal pattern of imprinting to cells
08/06/2003EP1332755A1 Taxol liposome composition for treatment of cancer and preparation thereof
08/06/2003EP1332751A1 Use of olive oil in the preparation of a product for oral hygiene for eliminating or reducing bacterial plaque and/or bacteria in the mouth
08/06/2003EP1332675A2 Synergistic microbicidal combinations
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332363A1 Detection of neurodegenerative disorders
08/06/2003EP1332246A2 Process for preparing low defect density silicon using high growth rates
08/06/2003EP1332151A1 Pyranoside derivatives
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332147A1 Thieno[2,3-c isoquinolines for use as inhibitors of parp
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332145A1 Process for formulation of antibiotic compounds
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332143A1 Polysubstituted imidazopyridines as gastric secretion inhibitors
08/06/2003EP1332142A1 Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]b enzyl]thiazolidine-2,4-dione
08/06/2003EP1332141A1 Quinazoline derivatives
08/06/2003EP1332139A2 Anticancer agents based on regulation of protein prenylation
08/06/2003EP1332137A2 Treatment of gastrointestinal stromal tumors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332133A1 Metabotropic glutamate receptor antagonists
08/06/2003EP1332132A2 Enamine derivatives as cell adhesion molecules
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332130A2 Atorvastatin hemi-calcium form vii
08/06/2003EP1332129A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332128A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists
08/06/2003EP1332127A2 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
08/06/2003EP1331972A2 Pharmaceutical compositions
08/06/2003EP1331960A2 Device and method for the cessation of smoking
08/06/2003EP1331947A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
08/06/2003EP1331946A2 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
08/06/2003EP1331945A2 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
08/06/2003EP1331937A2 Dibenzoxazepine alpha v integrin receptor antagonist
08/06/2003EP1331936A2 Mammalian metabolites of a tachykinin receptor antagonist
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1331934A1 Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes
08/06/2003EP1331933A2 The use of tiagabine for treatment of diabetic neuropathy and migraine
08/06/2003EP1331932A2 Therapeutic uses for ip 3? receptor-mediated calcium channel modulators
1 ... 5384 5385 5386 5387 5388 5389 5390 5391 5392 5393 5394 5395 5396 5397 5398 5399 5400 5401 5402 5403 5404 ... 7860